RxSight (RXST)
Market Price (10/7/2026): $4.88 | Market Cap: $202.5 MilSector: Health Care | Industry: Life Sciences Tools & Services
RxSight (RXST)
Market Price (10/7/2026): $4.88Market Cap: $202.5 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -103% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Personalized Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -127%, 3Y Excs Rtn is -166% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -55 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -43% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -13% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 25% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -18%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -21% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -28% Key risksRXST key risks include [1] significant regulatory delays and severe product adoption challenges, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -103% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -127%, 3Y Excs Rtn is -166% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -55 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -43% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -13% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 25% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -18%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -21% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -28% |
| Key risksRXST key risks include [1] significant regulatory delays and severe product adoption challenges, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 10/1/2026
RxSight (RXST) stock has lost about 5% since 6/30/2026 because of the following key factors:
1. Weak Q2 2026 Financial Results and Withdrawn Full-Year Guidance Created Uncertainty.
RxSight reported its Q2 2026 financial results on August 5, 2026, which showed a 19% year-over-year decline in product sales to $27.2 million and a 9% decrease in Light Adjustable Lens (LAL) unit volume to 24,917 units. The company's net loss widened slightly to $12.1 million, and product gross margin compressed to 71.2% from 74.9% in the prior-year period. Furthermore, in connection with a leadership transition, RxSight withdrew its 2026 full-year revenue guidance, contributing to investor uncertainty regarding future performance.
2. Acknowledged Commercial Execution Challenges and Leadership Transition Outlined a Turnaround.
Effective July 20, 2026, Aziz Mottiwala was appointed President and CEO. At the Wells Fargo Healthcare Conference on September 9, 2026, the new management openly acknowledged that "commercial execution has lagged, leaving the core business flat to declining" and outlined a "turnaround plan" which included intentions to double its U.S. sales force. This admission of underperformance and the need for a strategic reset likely weighed on the stock, as investors awaited clear signs of successful implementation and a return to growth. Management also declined to provide numeric guidance for fiscal year 2027, instead projecting formal guidance in early 2027.
Show more
RxSight (RXST) stock has lost about 5% since 6/30/2026 because of the following key factors:
1. Weak Q2 2026 Financial Results and Withdrawn Full-Year Guidance Created Uncertainty.
RxSight reported its Q2 2026 financial results on August 5, 2026, which showed a 19% year-over-year decline in product sales to $27.2 million and a 9% decrease in Light Adjustable Lens (LAL) unit volume to 24,917 units. The company's net loss widened slightly to $12.1 million, and product gross margin compressed to 71.2% from 74.9% in the prior-year period. Furthermore, in connection with a leadership transition, RxSight withdrew its 2026 full-year revenue guidance, contributing to investor uncertainty regarding future performance.
2. Acknowledged Commercial Execution Challenges and Leadership Transition Outlined a Turnaround.
Effective July 20, 2026, Aziz Mottiwala was appointed President and CEO. At the Wells Fargo Healthcare Conference on September 9, 2026, the new management openly acknowledged that "commercial execution has lagged, leaving the core business flat to declining" and outlined a "turnaround plan" which included intentions to double its U.S. sales force. This admission of underperformance and the need for a strategic reset likely weighed on the stock, as investors awaited clear signs of successful implementation and a return to growth. Management also declined to provide numeric guidance for fiscal year 2027, instead projecting formal guidance in early 2027.
Show more
Updated on 10/1/2026
RxSight (RXST) stock has lost about 5% since 6/30/2026 because of the following key factors:
1. Weak Q2 2026 Financial Results and Withdrawn Full-Year Guidance Created Uncertainty.
RxSight reported its Q2 2026 financial results on August 5, 2026, which showed a 19% year-over-year decline in product sales to $27.2 million and a 9% decrease in Light Adjustable Lens (LAL) unit volume to 24,917 units. The company's net loss widened slightly to $12.1 million, and product gross margin compressed to 71.2% from 74.9% in the prior-year period. Furthermore, in connection with a leadership transition, RxSight withdrew its 2026 full-year revenue guidance, contributing to investor uncertainty regarding future performance.
2. Acknowledged Commercial Execution Challenges and Leadership Transition Outlined a Turnaround.
Effective July 20, 2026, Aziz Mottiwala was appointed President and CEO. At the Wells Fargo Healthcare Conference on September 9, 2026, the new management openly acknowledged that "commercial execution has lagged, leaving the core business flat to declining" and outlined a "turnaround plan" which included intentions to double its U.S. sales force. This admission of underperformance and the need for a strategic reset likely weighed on the stock, as investors awaited clear signs of successful implementation and a return to growth. Management also declined to provide numeric guidance for fiscal year 2027, instead projecting formal guidance in early 2027.
3. Cautious Analyst Sentiment and Broader Ophthalmology Sector Pressures.
During the period, analyst sentiment remained largely cautious, with the consensus rating from 12 Wall Street analysts being "Reduce" (7 hold ratings, 3 sell ratings, and only 2 buy ratings). The average price target of $8.17, while above the stock's recent trading levels, reflected tempered expectations. This was compounded by external factors, including "heightened competitive trialing" and "broader pressure in the ophthalmology sector," which contributed to softer utilization trends for RxSight's products.
4. Strategic Alcon Collaboration and Next-Generation Product Development Provided a Floor for Valuation.
Despite the negative financial and operational news, RxSight announced a significant non-exclusive strategic collaboration with Alcon in July 2026 to develop and commercialize light-adjustable presbyopia-correcting intraocular lenses. This deal includes up to $200 million in upfront and milestone payments, with $60 million received by the end of Q2 2026, and substantial future royalty potential. Additionally, the company formally announced the development of its next-generation Light Adjustable Technology platform, aiming to improve workflow and reduce postoperative office visits. These long-term growth drivers likely acted as counteracting forces, preventing a more severe stock decline despite the immediate operational challenges.
Show less
RxSight (RXST) stock has lost about 5% since 6/30/2026 because of the following key factors:
1. Weak Q2 2026 Financial Results and Withdrawn Full-Year Guidance Created Uncertainty.
RxSight reported its Q2 2026 financial results on August 5, 2026, which showed a 19% year-over-year decline in product sales to $27.2 million and a 9% decrease in Light Adjustable Lens (LAL) unit volume to 24,917 units. The company's net loss widened slightly to $12.1 million, and product gross margin compressed to 71.2% from 74.9% in the prior-year period. Furthermore, in connection with a leadership transition, RxSight withdrew its 2026 full-year revenue guidance, contributing to investor uncertainty regarding future performance.
2. Acknowledged Commercial Execution Challenges and Leadership Transition Outlined a Turnaround.
Effective July 20, 2026, Aziz Mottiwala was appointed President and CEO. At the Wells Fargo Healthcare Conference on September 9, 2026, the new management openly acknowledged that "commercial execution has lagged, leaving the core business flat to declining" and outlined a "turnaround plan" which included intentions to double its U.S. sales force. This admission of underperformance and the need for a strategic reset likely weighed on the stock, as investors awaited clear signs of successful implementation and a return to growth. Management also declined to provide numeric guidance for fiscal year 2027, instead projecting formal guidance in early 2027.
3. Cautious Analyst Sentiment and Broader Ophthalmology Sector Pressures.
During the period, analyst sentiment remained largely cautious, with the consensus rating from 12 Wall Street analysts being "Reduce" (7 hold ratings, 3 sell ratings, and only 2 buy ratings). The average price target of $8.17, while above the stock's recent trading levels, reflected tempered expectations. This was compounded by external factors, including "heightened competitive trialing" and "broader pressure in the ophthalmology sector," which contributed to softer utilization trends for RxSight's products.
4. Strategic Alcon Collaboration and Next-Generation Product Development Provided a Floor for Valuation.
Despite the negative financial and operational news, RxSight announced a significant non-exclusive strategic collaboration with Alcon in July 2026 to develop and commercialize light-adjustable presbyopia-correcting intraocular lenses. This deal includes up to $200 million in upfront and milestone payments, with $60 million received by the end of Q2 2026, and substantial future royalty potential. Additionally, the company formally announced the development of its next-generation Light Adjustable Technology platform, aiming to improve workflow and reduce postoperative office visits. These long-term growth drivers likely acted as counteracting forces, preventing a more severe stock decline despite the immediate operational challenges.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -3.5% change in RXST stock from 6/30/2026 to 10/6/2026 was primarily driven by a -3.2% change in the company's P/S Multiple.| (LTM values as of) | 6302026 | 10062026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.82 | 4.65 | -3.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 127 | 128 | 0.1% |
| P/S Multiple | 1.6 | 1.5 | -3.2% |
| Shares Outstanding (Mil) | 41 | 41 | -0.4% |
| Cumulative Contribution | -3.5% |
Market Drivers
6/30/2026 to 10/6/2026| Return | Correlation | |
|---|---|---|
| RXST | -3.5% | |
| Market (SPY) | 4.3% | -3.1% |
| Sector (XLV) | 5.3% | 22.5% |
Fundamental Drivers
The -24.5% change in RXST stock from 3/31/2026 to 10/6/2026 was primarily driven by a -19.8% change in the company's P/S Multiple.| (LTM values as of) | 3312026 | 10062026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.16 | 4.65 | -24.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 134 | 128 | -5.1% |
| P/S Multiple | 1.9 | 1.5 | -19.8% |
| Shares Outstanding (Mil) | 41 | 41 | -0.8% |
| Cumulative Contribution | -24.5% |
Market Drivers
3/31/2026 to 10/6/2026| Return | Correlation | |
|---|---|---|
| RXST | -24.5% | |
| Market (SPY) | 20.1% | 12.2% |
| Sector (XLV) | 14.5% | 29.3% |
Fundamental Drivers
The -48.3% change in RXST stock from 9/30/2025 to 10/6/2026 was primarily driven by a -39.3% change in the company's P/S Multiple.| (LTM values as of) | 9302025 | 10062026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.99 | 4.65 | -48.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 147 | 128 | -13.2% |
| P/S Multiple | 2.5 | 1.5 | -39.3% |
| Shares Outstanding (Mil) | 41 | 41 | -1.8% |
| Cumulative Contribution | -48.3% |
Market Drivers
9/30/2025 to 10/6/2026| Return | Correlation | |
|---|---|---|
| RXST | -48.3% | |
| Market (SPY) | 17.9% | 23.1% |
| Sector (XLV) | 21.6% | 26.3% |
Fundamental Drivers
The -83.3% change in RXST stock from 9/30/2023 to 10/6/2026 was primarily driven by a -89.5% change in the company's P/S Multiple.| (LTM values as of) | 9302023 | 10062026 | Change |
|---|---|---|---|
| Stock Price ($) | 27.89 | 4.65 | -83.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 67 | 128 | 90.4% |
| P/S Multiple | 14.4 | 1.5 | -89.5% |
| Shares Outstanding (Mil) | 34 | 41 | -16.9% |
| Cumulative Contribution | -83.3% |
Market Drivers
9/30/2023 to 10/6/2026| Return | Correlation | |
|---|---|---|
| RXST | -83.3% | |
| Market (SPY) | 88.5% | 31.2% |
| Sector (XLV) | 35.9% | 25.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| RXST Return | -30% | 13% | 218% | -15% | -70% | -54% | -70% |
| Peers Return | 13% | -21% | -11% | -7% | 12% | 7% | -11% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 14% | 107% |
Monthly Win Rates [3] | |||||||
| RXST Win Rate | 17% | 50% | 67% | 58% | 25% | 30% | |
| Peers Win Rate | 58% | 56% | 47% | 47% | 58% | 47% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| RXST Max Drawdown | - | -40% | -37% | -48% | -81% | -56% | |
| Peers Max Drawdown | -29% | -35% | -36% | -30% | -31% | -25% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: JNJ, BLCO, STAA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 10/6/2026 (YTD)
How Low Can It Go
| Event | RXST | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -20.2% | -7.8% |
| % Gain to Breakeven | 25.3% | 8.5% |
| Time to Breakeven | 7 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -32.9% | -9.5% |
| % Gain to Breakeven | 49.0% | 10.5% |
| Time to Breakeven | 35 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -20.8% | -24.5% |
| % Gain to Breakeven | 26.3% | 32.4% |
| Time to Breakeven | 3 days | 427 days |
In The Past
RxSight's stock fell -20.2% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 25.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | RXST | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -20.2% | -7.8% |
| % Gain to Breakeven | 25.3% | 8.5% |
| Time to Breakeven | 7 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -32.9% | -9.5% |
| % Gain to Breakeven | 49.0% | 10.5% |
| Time to Breakeven | 35 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -20.8% | -24.5% |
| % Gain to Breakeven | 26.3% | 32.4% |
| Time to Breakeven | 3 days | 427 days |
In The Past
RxSight's stock fell -20.2% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 25.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About RxSight (RXST)
```html
RxSight, Inc. (RXST) is a medical technology company specializing in innovative solutions for cataract surgery patients. The company researches, develops, manufactures, and sells a proprietary Light Adjustable Lens (LAL) system designed to customize and enhance visual acuity after cataract removal.
The core of RxSight's offering is its RxSight system, which includes the LAL and an office-based RxSight Light Delivery Device. Unlike traditional intraocular lenses, the LAL's power can be precisely adjusted post-surgery using UV light delivered by the device. This unique feature allows doctors to fine-tune a patient's vision, customizing the lens based on visual correction needed to achieve optimal desired vision.
RxSight's primary customers are cataract doctors, both in the United States and internationally. By providing this advanced system, the company enables medical professionals to offer a personalized and highly effective approach to vision correction for their patients, aiming for superior and more predictable visual outcomes following cataract surgery.
```AI Analysis | Feedback
Cochlear (COH) for vision correction after cataract surgery.
Align Technology (ALGN) for personalized post-cataract vision optimization.
AI Analysis | Feedback
- Light Adjustable Intraocular Lenses (LAL): Intraocular lenses used in cataract surgery that can be customized post-surgery to achieve desired vision.
- RxSight System: A comprehensive system designed to enable doctors to customize and enhance visual acuity for patients after cataract surgery.
- RxSight Light Delivery Device: An office-based device that uses UV light in a programmed pattern to modify the LAL based on the visual correction needed.
AI Analysis | Feedback
RxSight (RXST) primarily sells its Light Adjustable Lenses (LALs) and the RxSight system to medical professionals and the facilities where they practice. Therefore, its major customers are not individual consumers but rather organizations within the healthcare sector. Based on the company description, these customers fall into the following categories:
- Cataract Surgeons and Ophthalmologists: These medical professionals are the direct users of the RxSight system and LALs, making purchasing decisions for their practices or the institutions they work for.
- Ophthalmology Clinics and Private Practices: These are specialized medical facilities focused on eye care, including cataract surgery, which acquire and implement the RxSight technology.
- Hospitals and Ambulatory Surgical Centers (ASCs): Larger healthcare institutions and outpatient surgical centers that have ophthalmology departments or dedicated eye surgery facilities are also key customers, purchasing the RxSight system for use in their surgical suites.
AI Analysis | Feedback
null
AI Analysis | Feedback
Ron Kurtz, MD, President & Chief Executive Officer
Dr. Kurtz has served as President and Chief Executive Officer of RxSight since January 2016. He previously co-founded LenSx Lasers, Inc., serving as President and CEO until its acquisition by Alcon Inc. in 2010. Following the acquisition, he became General Manager of Alcon LenSx, Inc. Dr. Kurtz also co-founded IntraLase Corp. in 1997, serving as its initial President & CEO. IntraLase became a publicly held NASDAQ-listed company in 2004 and was acquired by Advanced Medical Optics, Inc. in 2007. He has served on the faculty of the University of California, Irvine, and the University of Michigan.
Mark Wilterding, Chief Financial Officer
Mr. Wilterding was appointed Chief Financial Officer of RxSight, effective January 11, 2026. Prior to joining RxSight, he served as Senior Vice President of Global Finance for Edwards Lifesciences from 2019 to 2026, where his responsibilities included investor relations, financial planning and analysis, treasury, and regional finance. Before Edwards Lifesciences, he worked for Medtronic and spent the first 15 years of his career at Citi and Credit Suisse.
Eric Weinberg, Chief Business Development Officer
Mr. Weinberg transitioned to Chief Business Development Officer in October 2025, having previously served as Chief Commercial Officer since June 2015. He was a co-founder of LenSx Lasers, Inc. and served as its Chief Commercial Officer prior to its acquisition by Alcon Inc. He then served as Vice President of Surgical Development at Alcon LenSx, Inc. Mr. Weinberg also joined IntraLase Corp. in September 1999 as Vice President of Sales and Marketing.
Ilya Goldshleger, PhD, Chief Operating Officer
Dr. Goldshleger has served as RxSight's Chief Operating Officer since June 2019. He joined the company in September 2015 as Vice President, Engineering, and was responsible for the development of the Light Adjustable Lens (LAL) and Light Delivery Device (LDD) system. Before RxSight, Dr. Goldshleger held various management roles at Alcon LenSx, Inc. from 2010 to 2015, most recently as Director, R&D Optics and Diagnostics. He also held various research and development roles at LenSx Lasers, Inc.
Adam Dashe, Executive Vice President, International
Mr. Dashe leads RxSight's international business strategy and global market expansion. He has over 20 years of experience in the global medical device industry, with a focus on international growth and market development. Prior to joining RxSight, Mr. Dashe spent two decades at Edwards Lifesciences, where he notably led the company's Japan and Asia Pacific business operations.
AI Analysis | Feedback
```html
Key Business Risks for RxSight (RXST)
- Slowing Adoption and Sales of Light Delivery Devices (LDDs) and Light Adjustable Lenses (LALs): RxSight has experienced significant adoption challenges and a slowdown in the sales and utilization of its Light Delivery Devices (LDDs) and Light Adjustable Lenses (LALs). The company reported a 49% year-over-year drop in LDD sales in Q2 2025 and a 48% decline for the full year 2025. This deceleration in LDD placements is a critical concern as LDDs are the capital equipment necessary for performing LAL procedures, thereby potentially bottlenecking future LAL growth. These challenges have led to multiple downward revisions of the company's financial guidance for 2025 and 2026. Furthermore, these adoption issues have resulted in class-action lawsuits alleging that the company overstated demand for its products and failed to disclose these structural issues to investors.
- Intensifying Competition in the Premium Intraocular Lens (IOL) Market: RxSight operates in a rapidly evolving and increasingly competitive premium IOL market. The company faces significant competition from larger, established medical device companies such as Alcon, with its Unity and PanOptix Pro IOLs, and Johnson & Johnson, offering its TECNIS Odyssey IOL. Competitors like Rayner also offer advanced IOLs. These rivals possess broad product portfolios, established global distribution networks, and strong relationships with surgeons, making it challenging for RxSight to expand its market share and differentiate its unique post-operative adjustable LAL technology.
- Challenges in Achieving and Sustaining Profitability: Despite its innovative technology and historical revenue growth, RxSight continues to operate at a net loss. The company maintains high operating expenses, including substantial selling, general, and administrative (SG&A) costs driven by its sales force and significant non-cash stock-based compensation. While the Light Adjustable Lenses (LALs) boast strong gross margins, the decline in LDD sales and the necessary reallocation of resources to enhance LAL utilization within the existing customer base impact overall profitability. Although RxSight currently has a strong cash position, continuous unprofitability coupled with ongoing cash burn poses a long-term risk to its financial sustainability and investor confidence.
AI Analysis | Feedback
null
AI Analysis | Feedback
The addressable markets for RxSight's main products and services, primarily their Light Adjustable Intraocular Lenses (LAL) and associated systems for cataract surgery, are as follows:
- The global light-adjustable lens market size was estimated at USD 152 million in 2024. This market is projected to grow at a Compound Annual Growth Rate (CAGR) of 9.7% from 2025 to 2033, reaching a forecasted value of USD 352 million by 2033.
- In 2024, North America held the largest share of the global light-adjustable lens market, with a market value of approximately USD 62 million. Europe represented the second-largest regional market, with a value of approximately USD 45 million. The Asia Pacific region is emerging as the fastest-growing market, with a value of USD 32 million in 2024.
- The total addressable market for premium intraocular lenses was USD 2.4 billion globally in 2023 and is expected to grow at 11% annually.
- The estimated total addressable market for premium intraocular lenses in the non-U.S. region is USD 6.5 billion.
AI Analysis | Feedback
RxSight, Inc. (RXST) is expected to drive future revenue growth over the next 2-3 years through several key strategies and market dynamics:
- Increased Utilization of Light Adjustable Lenses (LALs) and Growth in Procedure Volumes: A primary driver for RxSight's revenue growth is the increasing utilization of its Light Adjustable Lenses (LALs) and the corresponding rise in procedure volumes. The company's business model relies on the sale of these consumable lenses, and management emphasizes driving faster utilization growth through internal initiatives and improved practice engagement. LAL revenue constituted an all-time high of 86% of total company sales in Q4 2025, and LAL unit sales increased by 12% in 2025.
- International Market Expansion: RxSight is strategically focused on expanding its presence in international markets. The company has secured regulatory approvals in key regions such as the EU, UK, South Korea, Singapore, and Australia, and anticipates revenue contributions from these areas. Efforts are also underway to gain approvals in major markets like China and Japan. The international market for Light Adjustable Lenses is estimated to be approximately double the size of the U.S. market, representing a significant long-term growth opportunity.
- Launch and Adoption of New Product Innovations: The introduction of new and enhanced versions of its Light Adjustable Lens technology, such as the Light Adjustable Lens+ (LAL+), is a critical driver for growth. The LAL+, commercially launched in April 2024, features a modified aspheric anterior surface designed to extend the depth of focus, further differentiating RxSight's offerings and potentially expanding its addressable market within the premium intraocular lens (IOL) segment.
- Growth of the Light Delivery Device (LDD) Installed Base and Market Share Expansion: An expanding installed base of Light Delivery Devices (LDDs) is foundational for increasing LAL procedure volumes, as each LDD represents a facility capable of performing LAL adjustments. By the end of 2025, RxSight's LDD installed base grew to 1,134 units, providing a strong platform for future procedure growth. Analysts also project that RxSight's differentiated and "best in class" adjustable IOL technology could enable the company to capture a substantial share of the U.S. premium IOL market, potentially growing from 10% to over 50% in the long term.
AI Analysis | Feedback
Share Issuance
- RxSight conducted an Initial Public Offering (IPO) in 2021.
- The number of shares outstanding increased significantly, from 19.07 million in 2020 to 27.35 million in 2021, representing a 43.41% increase.
- Shares outstanding continued to grow, reaching 35.66 million in 2023 (a 27.41% increase from 2022) and 40.96 million by the end of 2025.
Capital Expenditures
- Capital expenditures were reported as approximately $4 million in 2022, $5 million in 2023, and $5 million in 2024.
- In the latest 12 months, capital expenditures were -$3.83 million, and for the most recent quarter (Q4 2025), they totaled -$1.14 million.
- The primary focus of capital expenditures is on supporting the expanding commercial and operational footprint, including investments in Light Delivery Devices (LDDs) and research and development activities.
Peer Outperformance in Life Sciences Tools & Services
RXST has outperformed 50% of its 108 Life Sciences Tools & Services peers over 5Y. Among the peers that beat it is GH. Life Sciences Tools & Services ranks 8th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Life Sciences Tools & Services constituents that RXST has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
26%
of 126 industry peers · -45.2% return
3Y
23%
of 116 industry peers · -82.8% return
5Y
50%
of 108 industry peers · -64.8% return
Life Sciences Tools & Services peers with revenue growth within 4pp of RXST's that beat it on at least 2 of 3 windows, and by at least 20pp over 5Y. Growth is matched by construction, so the gap is largely a re-rating gap. The multiple column is the context for it.
| Ticker | Name | Rev Growth 3Y Avg | P/E | 1Y | 3Y | 5Y | 5Y Gap |
|---|---|---|---|---|---|---|---|
| RXST | RxSight | 28.8% | -4.1x | -45.2% | -82.8% | -64.8% | — |
| GH | Guardant Health | 32.6% | -50.0x | 169.3% | 499.3% | 53.0% | +118pp |
Price returns, excluding dividends. P/E shown for context only and not used for matching.
Median price return by industry across the Health Care sector, ranked by 5Y. Life Sciences Tools & Services is RXST's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 14.6% | 45.3% | 93.9% | CAH 427% · MCK 373% · COR 181% |
| Health Care Facilities | 24 | 0.4% | 5.6% | 9.6% | THC 307% · NHC 280% · ENSG 140% |
| Health Care Services | 20 | 20.8% | 36.1% | 8.3% | HIMS 296% · RDNT 144% · DGX 75% |
| Managed Health Care | 8 | 27.5% | -7.2% | 3.4% | OSCR 101% · HQY 40% · ELV 13% |
| Health Care Equipment | 50 | -8.4% | -2.5% | -18.3% | POCI 11150% · UFPT 370% · GKOS 252% |
| Pharmaceuticals | 62 | -7.8% | -6.9% | -32.6% | INDV 1105% · ETON 1034% · LQDA 842% |
| Health Care Supplies | 11 | 12.8% | -11.8% | -42.2% | LNTH 301% · HAE 51% · MMSI 17% |
| Life Sciences Tools & Services ← | 109 | -10.6% | -13.2% | -64.8% | SNWV 2022% · NTRA 244% · MEDP 212% |
| Biotechnology | 362 | -18.0% | -26.3% | -79.4% | CELZ 1186% · DNTH 1091% · ELVN 1027% |
| Health Care Technology | 20 | -31.9% | -55.1% | -80.7% | SPOK 79% · HSTM 11% · VEEV -2% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| RxSight Earnings Notes | 12/16/2025 | |
| Can RxSight Stock Hold Up When Markets Turn? | 10/17/2025 | |
| RXST Dip Buy Analysis | 07/10/2025 | |
| RxSight Stock Soars 27% In A Single Month, Now Is Not The Time To Buy The Stock | 05/16/2025 | |
| RxSight (RXST) Valuation Ratios Comparison | 05/15/2025 | |
| RxSight Total Shareholder Return (TSR): -14.7% in 2024 and 45.1% 3-yr compounded annual returns (above peer average) | 03/07/2025 | |
| RxSight (RXST) Operating Cash Flow Comparison | 02/17/2025 | |
| RxSight (RXST) Net Income Comparison | 02/16/2025 | |
| RxSight (RXST) Operating Income Comparison | 02/15/2025 | |
| RxSight (RXST) Revenue Comparison | 02/13/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 19.91 |
| Mkt Cap | 3.7 |
| Rev LTM | 2,832 |
| Op Inc LTM | 223 |
| FCF LTM | 65 |
| FCF 3Y Avg | -20 |
| CFO LTM | 227 |
| CFO 3Y Avg | 128 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.5% |
| Rev Chg 3Y Avg | 10.1% |
| Rev Chg Q | 7.8% |
| QoQ Delta Rev Chg LTM | 1.9% |
| Op Inc Chg LTM | 85.8% |
| Op Inc Chg 3Y Avg | 2.8% |
| Op Mgn LTM | 9.8% |
| Op Mgn 3Y Avg | -0.4% |
| QoQ Delta Op Mgn LTM | 1.0% |
| CFO/Rev LTM | 3.8% |
| CFO/Rev 3Y Avg | 2.1% |
| FCF/Rev LTM | 0.3% |
| FCF/Rev 3Y Avg | -3.5% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Research and development, manufacture and sale of light adjustable lenses and related capital | 134 | 140 | 89 | 49 | |
| Single segment | 23 | ||||
| Total | 134 | 140 | 89 | 49 | 23 |
| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Research and development, manufacture and sale of light adjustable lenses and related capital | -48 | -37 | -50 | -63 |
| Total | -48 | -37 | -50 | -63 |
| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Research and development, manufacture and sale of light adjustable lenses and related capital | -39 | -27 | -49 | -67 |
| Total | -39 | -27 | -49 | -67 |
Price Behavior
Price Behavior
| Market Price | $4.65 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 07/30/2021 | |
| Distance from 52W High | -64.5% | |
| 50 Days | 200 Days | |
| DMA Price | $5.96 | $6.95 |
| DMA Trend | down | up |
| Distance from DMA | -22.0% | -33.1% |
| 3M | 1YR | |
| Volatility | 58.7% | 63.1% |
| Downside Capture | 92.85 | 185.74 |
| Upside Capture | -22.97 | 83.24 |
| Correlation (SPY) | -0.8% | 23.3% |
RXST Betas & Captures as of 9/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.03 | 0.81 | -0.12 | 0.64 | 1.13 | 1.36 |
| Up Beta | -1.96 | -0.39 | -1.80 | 0.65 | 0.91 | 0.81 |
| Down Beta | 2.27 | 4.49 | 1.94 | 0.71 | 0.96 | 1.80 |
| Up Capture | -164% | 10% | 3% | 22% | 67% | 83% |
| Bmk +ve Days | 6 | 16 | 27 | 66 | 132 | 424 |
| Stock +ve Days | 8 | 19 | 30 | 59 | 116 | 362 |
| Down Capture | 375% | 208% | -7% | 113% | 143% | 112% |
| Bmk -ve Days | 16 | 26 | 37 | 60 | 120 | 328 |
| Stock -ve Days | 14 | 23 | 34 | 67 | 136 | 386 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RXST | |
|---|---|---|---|---|
| RXST | -47.3% | 63.0% | -0.77 | - |
| Sector ETF (XLV) | 16.9% | 15.7% | 0.79 | 26.3% |
| Equity (SPY) | 17.5% | 13.0% | 0.96 | 23.2% |
| Gold (GLD) | 6.9% | 29.6% | 0.23 | 7.4% |
| Commodities (DBC) | 46.1% | 20.8% | 1.71 | -11.0% |
| Real Estate (VNQ) | 2.1% | 13.7% | -0.10 | 28.0% |
| Bitcoin (BTCUSD) | -29.8% | 44.3% | -0.67 | 17.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RXST | |
|---|---|---|---|---|
| RXST | -18.3% | 66.8% | -0.01 | - |
| Sector ETF (XLV) | 7.1% | 15.2% | 0.28 | 27.6% |
| Equity (SPY) | 13.9% | 17.1% | 0.62 | 31.1% |
| Gold (GLD) | 18.7% | 18.9% | 0.80 | 3.4% |
| Commodities (DBC) | 10.3% | 19.5% | 0.40 | -0.2% |
| Real Estate (VNQ) | 1.2% | 18.8% | -0.04 | 27.4% |
| Bitcoin (BTCUSD) | 16.0% | 52.2% | 0.47 | 12.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RXST | |
|---|---|---|---|---|
| RXST | -11.1% | 68.6% | -0.03 | - |
| Sector ETF (XLV) | 10.6% | 16.7% | 0.51 | 25.8% |
| Equity (SPY) | 15.6% | 17.9% | 0.74 | 30.2% |
| Gold (GLD) | 11.6% | 16.4% | 0.58 | 4.2% |
| Commodities (DBC) | 8.3% | 18.1% | 0.37 | 0.7% |
| Real Estate (VNQ) | 4.2% | 20.7% | 0.16 | 26.7% |
| Bitcoin (BTCUSD) | 64.1% | 66.2% | 1.04 | 11.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/8/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/5/2026 | -3.3% | 12.2% | 4.0% |
| 5/6/2026 | -14.5% | -18.1% | -26.3% |
| 2/25/2026 | -10.1% | -10.0% | -26.3% |
| 7/8/2025 | -37.8% | -41.8% | -41.0% |
| 11/7/2024 | -5.6% | -13.2% | -22.0% |
| 5/6/2024 | -1.0% | -6.4% | -6.8% |
| 11/9/2023 | 6.2% | 18.2% | 47.2% |
| 8/7/2023 | 2.7% | 2.5% | 2.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 9 | 10 |
| # Negative | 9 | 9 | 8 |
| Median Positive | 6.7% | 10.0% | 10.8% |
| Median Negative | -5.6% | -13.0% | -21.5% |
| Max Positive | 28.2% | 24.0% | 48.9% |
| Max Negative | -37.8% | -41.8% | -41.0% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/5/2026 | -3.3% | 12.2% | 4.0% |
| 5/6/2026 | -14.5% | -18.1% | -26.3% |
| 2/25/2026 | -10.1% | -10.0% | -26.3% |
| 7/8/2025 | -37.8% | -41.8% | -41.0% |
| 11/7/2024 | -5.6% | -13.2% | -22.0% |
| 5/6/2024 | -1.0% | -6.4% | -6.8% |
| 11/9/2023 | 6.2% | 18.2% | 47.2% |
| 8/7/2023 | 2.7% | 2.5% | 2.4% |
| 5/9/2023 | 9.9% | 22.1% | 35.1% |
| 3/6/2023 | -2.9% | -6.1% | 8.0% |
| 1/9/2023 | 5.0% | 1.3% | 6.7% |
| 11/7/2022 | 6.7% | 10.0% | 9.5% |
| 8/8/2022 | -2.6% | -13.0% | -13.0% |
| 5/5/2022 | 7.0% | 9.1% | 48.9% |
| 3/8/2022 | 11.1% | -0.2% | 12.1% |
| 1/10/2022 | 28.2% | 24.0% | 42.9% |
| 11/10/2021 | 4.4% | 4.4% | -3.4% |
| 9/9/2021 | -16.1% | -18.7% | -21.1% |
| SUMMARY STATS | |||
| # Positive | 9 | 9 | 10 |
| # Negative | 9 | 9 | 8 |
| Median Positive | 6.7% | 10.0% | 10.8% |
| Median Negative | -5.6% | -13.0% | -21.5% |
| Max Positive | 28.2% | 24.0% | 48.9% |
| Max Negative | -37.8% | -41.8% | -41.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/05/2026 | 10-Q |
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 02/25/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 02/25/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/05/2024 | 10-Q |
| 03/31/2024 | 05/06/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/06/2023 | 10-K |
| 09/30/2022 | 11/07/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/05/2026 | 10-Q |
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 02/25/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 02/25/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/05/2024 | 10-Q |
| 03/31/2024 | 05/06/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/06/2023 | 10-K |
| 09/30/2022 | 11/07/2022 | 10-Q |
| 06/30/2022 | 08/08/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
| 12/31/2021 | 03/08/2022 | 10-K |
| 09/30/2021 | 11/10/2021 | 10-Q |
| 06/30/2021 | 09/09/2021 | 10-Q |
| 03/31/2021 | 07/30/2021 | 424B4 |
Insider Activity
Updated 9/16/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kurtz, Ronald M MD | Chief Medical Officer | Direct | Sell | 9022026 | 6.96 | 5,100 | 35,496 | 499,554 | Form |
| 2 | Wilterding, Mark | Chief Financial Officer | Direct | Sell | 9022026 | 6.96 | 7,765 | 54,044 | 174,341 | Form |
| 3 | Goldshleger, Ilya | Chief Operating Officer | Direct | Sell | 9022026 | 6.96 | 2,041 | 14,205 | 567,303 | Form |
| 4 | Weinberg, Eric | See remarks | Direct | Sell | 9022026 | 6.96 | 2,041 | 14,205 | 1,394,422 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kurtz, Ronald M MD | Chief Medical Officer | Direct | Sell | 9022026 | 6.96 | 5,100 | 35,496 | 499,554 | Form |
| 2 | Wilterding, Mark | Chief Financial Officer | Direct | Sell | 9022026 | 6.96 | 7,765 | 54,044 | 174,341 | Form |
| 3 | Goldshleger, Ilya | Chief Operating Officer | Direct | Sell | 9022026 | 6.96 | 2,041 | 14,205 | 567,303 | Form |
| 4 | Weinberg, Eric | See remarks | Direct | Sell | 9022026 | 6.96 | 2,041 | 14,205 | 1,394,422 | Form |
Investor Activity (13F)
Updated Oct 7, 202613F holdings as of Mar 31, 2026 (Q1 2026)
Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 10/6/2026